SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Jesse Owens

PatientJesse Owens
Date of birth1960-09-12
IdentifiersMRN HR-ML042-SYN; SSN (made up) 000-42-8319
Document date2026-05-26
AuthorClarence Whitfield-Arroyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Diagnosis visit: staging and biopsy results, the tumor board plan, and the thoracic oncology consultation. [S]

History of Present Illness

Mr. Owens returns two weeks after the screening CT. PET-CT three days after the scan showed the 2.9 cm left upper lobe nodule and a left interlobar node to be active, with nothing in the mediastinum or elsewhere, and brain MRI the next day was clear. Endobronchial ultrasound a week ago found adenocarcinoma in the interlobar node, with four other node stations negative. PD-L1 is 40 percent, and tissue sequencing, back yesterday, shows a KRAS G12C mutation and no EGFR, ALK or other targetable alteration. The thoracic tumor board reviewed him five days ago. He had pulmonary function tests this morning and saw Dr. Halvorsen-Pierce at midday. He still has his usual morning cough, no breathlessness, and has lost no weight. He is still smoking a pack a day and now wants to stop: the scan has convinced him. He has had no thoughts of self-harm. [S]

ElementDetail
DiagnosisAdenocarcinoma of the left upper lobe, cT1c N1 M0, stage IIB; resectable
Procedures since the first visitPET-CT, brain MRI, endobronchial ultrasound with systematic node sampling, pulmonary function tests
BiomarkersPD-L1 40 percent; KRAS G12C; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration
Tumor boardThree cycles of nivolumab with platinum chemotherapy, restaging, then lobectomy
His questionsWhether it can be cured; why surgery is not first; whether stopping smoking now makes any difference; whether he can keep speaking at schools

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo weight loss, fever or night sweats; weight 76.6 kg
RespiratoryPositiveUsual morning cough with a little clear sputum; no breathlessness or hemoptysis
CardiovascularNegativeNo chest pain or leg swelling
MusculoskeletalNegativeNo bone pain
NeurologicalNegativeNo headache, weakness or numbness
PsychiatricPositiveWorried but hopeful; PHQ-9 6, GAD-7 7; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 80.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7Oral route2026-05-26 to 2026-06-01completedS
Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the lastOne tablet dailyOral route2026-05-26 to 2026-08-05completedS
Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)1000 mcg once; a second dose was not due before pemetrexed endedIntramuscular route2026-05-26 to 2026-05-26completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-26Body height178cmS
2026-05-26Body weight76.6kgS
2026-05-26Body mass index (BMI) [Ratio]24.2kg/m2S
2026-05-26Systolic blood pressure130mm[Hg]S
2026-05-26Diastolic blood pressure80mm[Hg]S
2026-05-26Heart rate80/minS
2026-05-26Respiratory rate16/minS
2026-05-26Body temperature36.6CelS
2026-05-26Oxygen saturation in Arterial blood by Pulse oximetry95%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-26Hemoglobin [Mass/volume] in Blood14.9g/dL13.5-17.5 g/dLNormalS
2026-05-26Leukocytes [#/volume] in Blood by Automated count8.110*3/uL4-11 10*3/uLNormalS
2026-05-26Neutrophils [#/volume] in Blood by Automated count5.210*3/uL1.5-7.7 10*3/uLNormalS
2026-05-26Platelets [#/volume] in Blood by Automated count25810*3/uL150-400 10*3/uLNormalS
2026-05-26Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.7-1.3 mg/dLNormalS
2026-05-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-26Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
2026-05-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L7-55 U/LNormalS
2026-05-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-48 U/LNormalS
2026-05-26Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-05-26Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4 mIU/LNormalS
2026-05-26Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-05-26Cortisol [Mass/volume] in Serum or Plasma13.8ug/dLMorning (8 a.m.) reference intervalNormalS
2026-05-26FEV12.71LLower limit of normal for his age and height (GLI 2012)NormalS
2026-05-26FEV1 measured/predicted86%>=80%NormalS
2026-05-26FEV1/FVC0.73{ratio}Below 0.70 after bronchodilator indicates airflow obstructionNormalS
2026-05-26Diffusion capacity.carbon monoxide23.6mL/min/mm[Hg]Lower limit of normal for his age and height; predicted 27.4NormalS
2026-05-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-05-26Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S

Physical Exam

Vital signs recorded on 2026-05-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell and upright; weight 76.6 kg; blood pressure 130/80, pulse 80; oxygen saturation 95 percent
Lymph nodesNo supraclavicular or cervical nodes
RespiratoryBreath sounds equal; scattered early-morning rhonchi that clear with a cough; no wheeze
CardiovascularRegular rhythm; no murmur; no edema
ExtremitiesNo clubbing
PsychiatricAttentive, asks direct questions and writes the answers down

Problems

ProblemClinical statusVerificationCodeProvenance
Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review bookedresolvedconfirmed R91.1S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit.
Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alterationactiveconfirmed C34.12S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable.
Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicineactiveconfirmed F17.210S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryTissue diagnosis, PD-L1 and comprehensive biomarker testingAt diagnosis, before any systemic therapy; EGFR and ALK must be negative before chemoimmunotherapyUp to dateAdenocarcinoma (TTF-1 positive); PD-L1 40 percent; KRAS G12C; EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK and HER2 negative on tissue and plasma
ImagingStaging FDG PET-CT and brain MRIAt diagnosis for stage II or higherUp to dateNo mediastinal or distant disease on PET-CT; brain MRI clear
ExaminationInvasive mediastinal stagingBefore treatment when a central tumor or a positive hilar node is present (ACCP)Up to dateEBUS: 11L positive; 4R, 4L, 7 and 10L negative
ReferralThoracic multidisciplinary tumor board and thoracic surgeryBefore treatment of every potentially resectable cancerUp to dateTumor board five days ago; thoracic surgery review booked after cycle 2
ImagingPulmonary function: spirometry and DLCO with predicted postoperative valuesBefore lung resectionCompleted todayFEV1 2.71 L (86 percent), FEV1/FVC 0.73, DLCO 23.6 (86 percent); predicted postoperative FEV1 and DLCO 63 percent: low risk, no exercise test needed
LaboratoryImmune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucoseBaseline, then before each immunotherapy infusionCompleted todayTSH 1.9, free T4 1.2; ALT 23, AST 22, bilirubin 0.6; creatinine 1.0, eGFR 84; glucose 97
LaboratoryMorning cortisolBaseline and before each immunotherapy infusion (CMID); for symptomsCompleted today13.8 mcg/dL at 8 a.m.
LaboratoryBlood count with neutrophils and plateletsBaseline, then before each chemotherapy cycleCompleted todayHemoglobin 14.9, white cells 8.1, neutrophils 5.2, platelets 258
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore systemic cancer therapyCompleted todayDrawn today; results to the oncology team before cycle 1
Self-managementTobacco use and cessation treatmentEvery visitCompleted todayStill smoking a pack a day; ready to quit; varenicline started with a quit date of day 1 of cycle 1; quitline enrolled
SurveyDistress and depression screeningEvery visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitionsCompleted todayPHQ-9 6 (item 9 scored 0), GAD-7 7; worried, supported at home
ExaminationDyspnea and cough assessmentEvery visitCompleted todayUsual morning cough; no breathlessness
Self-managementPulmonary rehabilitation (prehabilitation)Before and after lung resectionReferredTwice-weekly program from next week, alongside chemotherapy
ReferralSpecialist palliative careEarly, for advanced or high-symptom-burden cancerNot indicatedResectable cancer treated with curative intent and no symptom burden; symptoms and distress are screened at each visit and referral will follow if needs arise
ImagingSurveillance CT; routine brain MRI; PET-CT and ctDNA for surveillanceAfter curative treatmentNot indicatedNot yet applicable; PET-CT and circulating markers are not used for surveillance
Self-managementEquity: navigation and time to treatmentEach step of the pathwayCompleted todayDiagnosis and plan 15 days after the screening CT; treatment starts in eight days; nurse navigator and transport help in place

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20, before chemoimmunotherapy [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e211S-e250S (PMID 23649440) (2013); Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013); Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). N Engl J Med 2022;386(21):1973-1985 (PMID 35403841) (2022); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)

Follow-up: Cycle 1 in eight days, on his quit date. Visit at cycle 2. Call the 24-hour oncology line for fever, breathlessness, a new cough, diarrhea, rash, yellow eyes or severe tiredness. Next scheduled visit 2026-06-24: day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitation. [S]